Dr Zezos and colleagues from Greece evaluated safety and efficacy of low-molecular-weight heparin as adjuvant therapy in active ulcerative colitis.
The investigative included 34 adult patients with active ulcerative in a prospective, randomized, comparative study, and treated for 12 weeks.
The team randomized 18 patients to the 'standard therapy' group, who were treated with aminosalicylates and weekly tapered corticosteroids.
| Disease improvement was seen in 65% of the heparin therapy group|
|Alimentary Pharmacology & Therapeutics|
The 'heparin therapy' group included 16 patients treated with standard therapy plus enoxaparin 100 Anti-Xa IU/kg/day subcutaneously.
The team reported that 17 patients in the 'standard therapy' group and 15 patients in the 'heparin therapy' group completed the study.
The investigators found that tolerability and compliance to therapy were excellent.
The team noted no withdrawals due to complications.
There was a significant improvement in the disease severity in both groups, without any difference between them.
The team observed disease improvement in 65% with heparin, and 73% receiving standard therapy.
There were no significant differences in inflammation and coagulation parameters during and at the end of the study between treatment groups.
Dr Zezos' team concluded, “Adjuvant administration of low-molecular heparin in patients with active ulcerative colitis is safe and well tolerated, but no additive benefit over standard therapy for ulcerative colitis was noted.”